関連する実験動画
Updated: Feb 22, 2026

23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.6K
抗血栓性治療の時間的なパターンと,心房細動に関連した脳卒中後の臨床結果
Keon-Joo Lee1, Hoonji Oh2, Han-Gil Jeong3
1Department of Neurology Korea University Guro Hospital Seoul Korea.
Journal of the American Heart Association
|February 20, 2026
まとめ
動脈動性脳卒中に対する抗血栓剤戦略は,ビタミンK非抗体である経口抗凝固剤単独療法へと進化し,より良い結果を示した. このシフトにより,脳卒中後の重要な初期期間に患者のケアが改善されました.
科学分野:
- 心臓病学 心臓病学
- 神経学 神経学とは
- 薬理学 薬理学とは
背景:
- 心房細動を伴う急性性性血性脳卒中患者の抗血栓治療における時間的傾向を調査した.
- これらの戦略と臨床結果の関連性を調べました.
研究 の 目的:
- 動脈動に関連した急性性缺血性脳卒中後の抗血栓治療戦略の進化を記述する.
- これらの進化する治療パターンに関連した臨床的アウトカムを評価する.
主な方法:
- 2965人の急性不全性脳卒中および心房細動の患者を対象とした多センター前向きコホート研究.
- フォローアップデータは,平均1.92年にわたって収集されました.
- プライマリアウトカム:再発性脳卒中,心筋梗塞,全因死亡の複合;二次アウトカム:個々の構成要素と大出血.
主要な成果:
- 最初の抗血栓剤の戦略は多様で,抗血小板剤のみの治療は48時間以内に最も一般的であった (50.9%).
- 非ビタミンKアンタゴニストによる経口抗凝固剤単独治療は,放出によって優勢となり (65.7%) 持続した.
- 非ビタミンKアンタゴニストによる経口抗凝固剤単独治療は,抗血小板のみまたは抗血栓剤なしの治療と比較して,プライマリエンドポイントのより低い発生率と関連していました.
結論:
- 動脈動性脳卒中患者に対する抗血栓治療戦略は,非ビタミンKアンタゴニストの経口抗凝固剤単独療法へと進化した.
- 治療の選択は,特に脳卒中後の早期の高リスク期間の臨床結果に大きく影響しました.
関連する概念動画
Venous Thrombosis III: Interprofessional Care
395
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
395
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
405
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
405
Venous Thrombosis IV: Nursing Management
285
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
285

